Peter Emtage

Peter Emtage is the CEO and Founder of Santa Ana Bio and a Venture Partner at Versant Ventures, based in Santa Ana, California. In June 2024, he led Santa Ana Bio out of stealth with $168 million in Series A and B funding to advance three precision immunology programs into clinical trials by 2025. Previously, he served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company, and was the Chief Scientific Officer at Cell Design Labs prior to its acquisition by Gilead. His earlier career includes serving as Vice President of Immune Mediated Therapy at MedImmune and completing a postdoctoral fellowship at the National Cancer Institute. Emtage leverages over 25 years of drug development experience to focus on translational research and novel therapies for oncology, autoimmunity, and inflammatory diseases.